Last edition
News about "Degrader-Antibody Conjugate (DAC)"
Orum Therapeutics Doses First Patient in ORM-1153 Trial
Orum Therapeutics has dosed the first patient in its phase 1 ORM-1153 trial for relapsed or refractory AML and other CD123-expressing blood cancers.
Degrader-Antibody Conjugate (DAC) | 14/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members